ManuScript Details
|
Paper Id:
|
IJCIRAS1491
|
|
Title:
|
EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY
|
| Published in: |
International Journal Of Creative and Innovative Research In All Studies |
| Publisher: |
IJCIRAS |
| ISSN: |
2581-5334 |
| Volume / Issue: |
Volume 2 Issue 8 |
| Pages: |
1
|
| Published On: |
1/27/2020 11:38:28 PM (MM/dd/yyyy) |
| PDF Url: |
http://www.ijciras.com/PublishedPaper/IJCIRAS1491.pdf |
Main Author Details
|
Name:
|
Kheira REKAI |
| Institute: |
Establishment university hospital of Oran |
Co - Author Details
| Author Name |
Author Institute |
| Terki Khadidja |
Establishment university hospital of Oran |
Abstract
|
Research Area:
|
Oncology |
| KeyWord: |
Metastatic Breast cancer HER + , Trastuzumab , vinorelbine |
| Abstract: |
Introduction : chemotherapy plus trastuzumab (H) is the standard first line treatment for HER2-positive MBC . Trastuzumab plus vinorelbine regimen is among the most active and well-tolerated options in this setting. The all-oral chemotherapy combination has shown activity and good tolerance in MBC. The aim of our study is to analyze the epidemiological and clinical data ; and to evaluate effectiveness safety and tolerance of trastuzumab plus oral vinorelbine in MBC HER2+ .
Methods: we retrospectively reviewed all patients with HER2+ MBC who received oral vinorelbine with trastuzumab at our institution between January 2016 and March 2019 .
Vinorelbine was given as a 80mg/m² dose(following a first cycle at 60mg/m² D1&D8 every 3weeks,trastuzumab at 8mg/kg on D1 (loading dose) then 6mg/kg iv every 3weeks.
Results: we identified 66 patients treated from January 2016 to March 2019 . Median age was 43 years (32-75) (60%≤50Y). All patients had invasive ductal histology. All tumours were HER2+ by immunohistochemistry and 65% were HR negative.
Other patients characteristics were: prior (neo)adjuvant CT 80%;prior trastuzumab 55%; visceral involvement 65% ; ≥2 metastatic sites 50%; median number of vinorelbine administrations 17 (range 9-32); 65% of patients received more than 6cycles.
Adverse events: G1/2: neutropenia 25%, vomiting 15%, asthenia 10% and LVEF decline 10%. Efficacy: objective response rate 80%, CR15%, PR 35%, SD 30%, PD 20%. Median progression-free survival was 12 months (2, 5- 34 months)
Conclusion: The oral regimen of vinorelbine with trastuzumab has shown high anti-tumoral efficacy in pts with HER2-positive MBC. Toxicity profile was acceptable, with in particular, a very low rate of alopecia. Full treatment could be maintained until progression of the disease in the majority of patients.
|
Citations
Copy and paste a formatted citation or use one of the links to import into a bibliography manager and reference.
|
IEEE
|
Kheira REKAI, Terki Khadidja, "EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY", International Journal Of Creative and Innovative Research In All Studies,
vol. 2, no. 8, pp. 44-44, 2020.
|
|
MLA
|
Kheira REKAI, Terki Khadidja "EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY." International Journal Of Creative and Innovative Research In All Studies,
vol 2, no. 8, 2020, pp. 44-44.
|
|
APA
|
Kheira REKAI, Terki Khadidja (2020). EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY. International Journal Of Creative and Innovative Research In All Studies,
2(8), 44-44.
|
EFFICACY AND SAFETY OF TRASTUZUMAB IN COMBINATION TO ORAL VINORELBINE IN METASTATIC BREAST CANCER OVER EXPRESSED HER2 : A RETROSPECTIVE STUDY
Number Of Downloads - 3
Last downloaded on 15/06/2020
